Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. SciClone Pharmaceuticals (Holdings) Limited
  6. News
  7. Summary
    6600   KYG4271B1023

SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

(6600)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SciClone Pharmaceuticals Limited submits the Biologics License Application for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the National Medical Products Administration (“NMPA”) of China

07/06/2021 | 09:01am EST

Y-mAbs Therapeutics Inc. announced that SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has submitted the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the National Medical Products Administration (“NMPA”) of China. Researchers at MSK developed DANYELZA®, which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the product.


© S&P Capital IQ 2021
All news about SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
2021SciClone Pharmaceuticals Grants Nearly 4 Million Share Options
MT
2021SCICLONE PHARMACEUTICALS LIMITED(SEH : 6600) added to S&P Global BMI Index
CI
2021SCICLONE PHARMACEUTICALS : Wins License for Preclinical Miniature Solid Tumor Inhibitor
MT
2021Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in..
AQ
2021SCICLONE PHARMACEUTICALS : Gets Priority Review for Neuroblastoma Treatment in China
MT
2021NMPA Grants Priority Review to BLA of DANYELZA®
CI
2021610,329,800 Ordinary Shares of SciClone Pharmaceuticals Limited are subject to a Lock-U..
CI
2021Sciclone Pharmaceuticals Limited Announces Unaudited Consolidated Financial Results for..
CI
2021ThinkGeek Network Technology Files for Hong Kong IPO
MT
2021Beijing Evercare Medical Files for Hong Kong IPO
MT
More news
Financials
Sales 2021 2 437 M 386 M 386 M
Net income 2021 891 M 141 M 141 M
Net cash 2021 719 M 114 M 114 M
P/E ratio 2021 5,13x
Yield 2021 5,64%
Capitalization 4 589 M 726 M 726 M
EV / Sales 2021 1,59x
EV / Sales 2022 1,16x
Nbr of Employees 850
Free-Float -
Chart SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Duration : Period :
SciClone Pharmaceuticals (Holdings) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 6,80 CNY
Average target price 13,38 CNY
Spread / Average Target 96,7%
EPS Revisions
Managers and Directors
Hong Zhao President, CEO & Executive Director
Zhen Fu Li Chairman
Ping Chen Independent Non-Executive Director
Wendy Hayes Independent Non-Executive Director
Guo En Liu Independent Non-Executive Director
Sector and Competitors